Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Mar 9:13:868174.
doi: 10.3389/fendo.2022.868174. eCollection 2022.

Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Renzhi Wang  1 , Cuiqi Zhou  2 , Ann I McCormack  3 , Adam N Mamelak  4
Affiliations
Editorial

Editorial: Refractory Pituitary Adenoma-Current Challenges and Emerging Treatments

Renzhi Wang et al. Front Endocrinol (Lausanne). .
No abstract available

Keywords: diagnosis; drug resistance; medical therapy; pathogenesis; refractory pituitary adenomas; surgical treatment; temozolomide, targeted and immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past collaboration with several of the authors (AIM, ANM).

Comment on

  • Editorial on the Research Topic Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments

References

    1. Dai C, Feng M, Liu X, Ma S, Sun B, Bao X, et al. Refractory Pituitary Adenoma: A Novel Classification for Pituitary Tumors. Oncotarget (2016) 7(50):83657–68. doi: 10.18632/oncotarget.13274 - DOI - PMC - PubMed
    1. Liu X, Dai C, Feng M, Li M, Chen G, Wang R. Diagnosis and Treatment of Refractory Pituitary Adenomas: A Narrative Review. Gland Surg (2021) 10(4):1499–507. doi: 10.21037/gs-20-873 - DOI - PMC - PubMed
    1. Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, Micko A, et al. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. J Clin Endocrinol Metab (2020) 105(3):e660–e675. doi: 10.1210/clinem/dgz211 - DOI - PubMed
    1. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas. Eur J Endocrinol (2018) 178(1):G1–G24. doi: 10.1530/EJE-17-0796 - DOI - PubMed
    1. Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A, Brown PD, et al. Treatment and Long-Term Outcomes in Pituitary Carcinoma: A Cohort Study. Eur J Endocrinol (2019) 181(4):397–407. - PubMed

Publication types

LinkOut - more resources